topic

384 A Phase 1 study to evaluate the safety, PK, and antitumor activity of AK117, an anti-CD47 monoclonal antibody, in subjects with relapsed/refractory advanced or metastatic solid tumors or lymphomas
Amy Prawira, Jermaine Coward, Anna Mislang, Adnan Nagrial, Hui Gan, Xiaoping Jin, Baiyong Li, Zhongmin Maxwell Wang, Kon Yew Kwek, Dennis Xia, Yu Xia

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A233; DOI: 10.1136/jitc-2020-SITC2020.0384
385 A first-in-human study of lemzoparlimab, a differentiated anti-CD47 antibody, in subjects with relapsed/refractory malignancy: initial monotherapy results
Jordan Berlin, Wael Harb, Alex Adjei, Yan Xing, Paul Swiecicki, Mahesh Seetharam, Lakshminarayanan Nandagopal, Ajay Gopal, Cong Xu, Cong Xu, Yuan Meng, Linda Lee, Yonggang Zhao, Zhengyi Wang, Joan Huaqiong Shen

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A233-A234; DOI: 10.1136/jitc-2020-SITC2020.0385
386 Phase I/Ib first-in-human study of HEK-NIZ985, a recombinant IL-15/IL-15Rα heterodimer, alone and in combination with spartalizumab, in adults with advanced and metastatic solid tumors
Rom Leidner, Andrea Wang-Gillam, Sumati Gupta, Robert Wesolowski, Douglas McNeel, Kevin Conlon, Nehal Parikh, Jessica O’Keeffe, Niladri Roy Chowdhury, Xiaoli Wang, Ryan Sullivan, John Thompson

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A234-A235; DOI: 10.1136/jitc-2020-SITC2020.0386
387 A Phase II, multicenter study of the safety and efficacy of LAG525 in combination with spartalizumab in patients with advanced malignancies
Chia-Chi Lin, Elena Garralda, Patrick Schöffski, David Hong, Lillian Siu, Miguel Martin, Michela Maur, Rina Hui, Ross Soo, Joanne Chiu, Tian Zhang, Brigette Ma, Chrisann Kyi, Daniel Tan, Philippe Cassier, John Sarantopoulos, Andrew Weickhardt, Rich Carvajal, Jennifer Spratlin, Taito Esaki, Fréderic Rolland, Wallace Akerley, Barbara Deschler-Baier, Catherine Sabatos-Peyton, Niladri Roy Chowdhury, Daniel Gusenleitner, Eunice Kwak, Vasileios Askoxylakis, Filippo De Braud

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A235; DOI: 10.1136/jitc-2020-SITC2020.0387
391 A first-in-human study of intratumoral SAR441000, an mRNA mixture encoding IL-12sc, interferon alpha2b, GM-CSF and IL-15sushi as monotherapy and in combination with cemiplimab in advanced solid tumors
Oliver Bechter, Jochen Utikal, Jean-Francois Baurain, Christophe Massard, Ugur Sahin, Evelyna Derhovanessian, Marie-Laure Ozoux, Rahul Marpadga, Esteban-Rodrigo Imedio, Nicolas Acquavella, Carmen Loquai

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A237-A238; DOI: 10.1136/jitc-2020-SITC2020.0391
392 Phase 1 study of CI-8993 anti-VISTA antibody in patients with advanced solid tumor malignancies
Elizabeth Martinez, Jason Faris, Reinhard Von Roemeling, Steven Angelides, Melissa Johnson

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A238-A239; DOI: 10.1136/jitc-2020-SITC2020.0392
394 Interleukin-8–neutralizing monoclonal antibody BMS-986253 plus nivolumab (NIVO) in biomarker-enriched, primarily anti–PD-(L)1–experienced patients with advanced cancer: initial phase 1 results
Diwakar Davar, Matteo Simonelli, Martin Gutierrez, Emiliano Calvo, Jason Melear, Sarina Piha-Paul, Donald Richards, Matthew Dallos, Janaki Parameswaran, Vinit Kumar, Xiaochen Zhao, Santanu Dutta, Ignacio Melero

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A239-A240; DOI: 10.1136/jitc-2020-SITC2020.0394
393 First-in-human phase 1/2a study of the novel nonfucosylated anti–CTLA-4 monoclonal antibody BMS-986218 ± nivolumab in advanced solid tumors: initial phase 1 results
Claire Friedman, Paolo Ascierto, Diwakar Davar, Mark O’Hara, Ronnie Shapira-Frommer, Matthew Dallos, Vivek Khemka, Lee James, Bruce Fischer, Shilpa Demes, Li Li, Martin Kozicki, Palanikumar Ravindran, Ke Xu, Georgia Kollia, Jacqueline Shoukry, Mona Yunan, Ashish Massey, Martin Gutierrez

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A239; DOI: 10.1136/jitc-2020-SITC2020.0393
40 The orion™ platform from rarecyte® enables same-day 21-plex fluorescence tissue analysis
Daniel Campton, Jeremy Cooper, Steven Reese, Kyla Teplitz, Jeffrey Werbin, Joshua Nordberg, Eric Kaldjian, Tad George

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A24; DOI: 10.1136/jitc-2020-SITC2020.0040
41 Optimization of an ultrasensitive, quantitative immunoassay for detection of CD20 in non-hodgkin’s lymphoma (NHL) FFPE samples
Apollina Goel, Michael Ross, Jeanette Rheinhardt, Peter Duval, Michael Maker, Hiroyuki Yokota, Kenneth Bloom, George Abe, Ann Ranger, Joseph Krueger

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A24; DOI: 10.1136/jitc-2020-SITC2020.0041

Main menu

topic

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

topic

Pages